Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$----
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
Debt to Equity
--
ROE
--
ROCE
--
Div. Yield
--
Book Value
--
EPS
--
CFO
$-67.81 Mln
EBITDA
$-94.70 Mln
Net Profit
$-107.54 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Alpha Tau Medical Ltd. Warrant (DRTSW)
| 4.71 | -4.68 | -35.32 | 4.81 | -25.83 | -- | -- |
|
BSE Sensex*
| 2.65 | 3.75 | 5.82 | 8.94 | 11.77 | 20.12 | 11.36 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
|
|---|---|---|
|
Alpha Tau Medical Ltd. Warrant (DRTSW)
| 8.96 | -22.99 |
|
S&P Small-Cap 600
| 7.01 | 13.89 |
|
BSE Sensex
| 8.10 | 18.74 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT... technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel. Read more
CEO & Chairman
Mr. Uzi Sofer
CEO & Chairman
Mr. Uzi Sofer
Headquarters
Jerusalem
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Alpha Tau Medical Ltd Warrant (DRTSW) is $0.22 (NASDAQ) as of 28-Apr-2025 16:00 EDT. Alpha Tau Medical Ltd Warrant (DRTSW) has given a return of -25.83% in the last 3 years.
Alpha Tau Medical Ltd Warrant (DRTSW) has a market capitalisation of -- as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Alpha Tau Medical Ltd Warrant (DRTSW) and enter the required number of quantities and click on buy to purchase the shares of Alpha Tau Medical Ltd Warrant (DRTSW).
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical or pending clinical studies for brain and other cancers. The company is headquartered in Jerusalem, Israel.
The CEO & director of Mr. Uzi Sofer. is Alpha Tau Medical Ltd Warrant (DRTSW), and CFO & Sr. VP is Mr. Uzi Sofer.
There is no promoter pledging in Alpha Tau Medical Ltd Warrant (DRTSW).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|
| Alpha Tau Medical Ltd. Warrant (DRTSW) | Ratios |
|---|---|
|
Return on equity(%)
|
--
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Alpha Tau Medical Ltd Warrant (DRTSW) was $0 Mln.
$0.01
(
